← Human Trials & Peer-Reviewed Studies
Effect of galanin on the growth hormone (GH) response to GH-releasing hormone in patients with Cushing's disease.
Plain-language guide to PMID 7681769 (1993): single-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 5 subjects.
Key Facts
- PMID
- 7681769
- Journal
- Endocrine research
- Year
- 1993
- Study type
- Randomized Controlled Trial
- Authors
- Giustina A et al. (5 authors)
- DOI
- 10.1080/07435809309035407
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in this randomized controlled trial publication.
The aim of their study was to investigate the effects of galanin on the GH response to GHRH in patients with Cushing's disease.
Why It Was Studied
Attenuated plasma GH secretion during sleep and blunted GH responses to provocative stimuli have been observed in patients with Cushing's disease.
Synthetic porcine galanin elicits GH secretion when given alone, and enhances the GH response to GHRH in normal human subjects.
Who Took Part
According to the abstract, 5 subjects were involved.
By PubMed's age tags, the people studied were adults and middle-aged adults, women only.
How the Study Was Run
The researchers set it up as a randomized and single-blind study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Only one side, usually the subjects, was kept unaware of whether Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was given.
What Was Measured
The subject headings attached to it are Adenoma, Analysis of Variance, Cushing Syndrome, Galanin, Growth Hormone, Growth Hormone-Releasing Hormone and Neuropeptides.
What This Means in Plain Language
The paper is a randomized and single-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 5 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1993 (Endocrine research), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.
Our Notes on the Compounds
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
Related Pages
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
- GHRH (Growth Hormone-Releasing Hormone) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.